56 results found
Gomes AC, Baraniak IA, McIntosh MR, et al., 2023, A temperature-dependent virus-binding assay reveals the presence of neutralizing antibodies in human cytomegalovirus gB vaccine recipients' sera, JOURNAL OF GENERAL VIROLOGY, Vol: 104, ISSN: 0022-1317
McLean GRR, Zhang Y, Ndoyi R, et al., 2022, Rapid Quantification of SARS-CoV-2 Neutralising Antibodies Using Time-Resolved Fluorescence Immunoassay, VACCINES, Vol: 10
McLean G, Kamil J, Lee B, et al., 2022, The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines, MBIO, Vol: 13, ISSN: 2150-7511
Touabi L, Mclean GR, 2021, Antibody responses to human rhinovirus induced by different vaccine platforms, Publisher: WILEY, Pages: 177-177, ISSN: 0014-2980
Bakkar MR, Faraag AHI, Soliman ERS, et al., 2021, Rhamnolipids Nano-Micelles as a Potential Hand Sanitizer, ANTIBIOTICS-BASEL, Vol: 10, ISSN: 2079-6382
Touabi L, Aflatouni F, McLean GR, 2021, Mechanisms of Rhinovirus Neutralisation by Antibodies, VIRUSES-BASEL, Vol: 13
Siddiqui S, Hackl S, Ghoddusi H, et al., 2021, IgA binds to the AD-2 epitope of glycoprotein B and neutralizes human cytomegalovirus, IMMUNOLOGY, Vol: 162, Pages: 314-327, ISSN: 0019-2805
Abo-zeid Y, Williams GR, Touabi L, et al., 2020, An investigation of rhinovirus infection on cellular uptake of poly (glycerol-adipate) nanoparticles, INTERNATIONAL JOURNAL OF PHARMACEUTICS, Vol: 589, ISSN: 0378-5173
Abo-zeid Y, Ismail NSM, McLean GR, et al., 2020, A molecular docking study repurposes FDA approved iron oxide nanoparticles to treat and control COVID-19 infection, EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, Vol: 153, ISSN: 0928-0987
McLean GR, 2020, Vaccine strategies to induce broadly protective immunity to rhinoviruses, HUMAN VACCINES & IMMUNOTHERAPEUTICS, Vol: 16, Pages: 684-686, ISSN: 2164-5515
Urban S, Paragi G, Burian K, et al., 2020, Identification of similar epitopes between severe acute respiratory syndrome coronavirus-2 and Bacillus Calmette-Guerin: potential for cross-reactive adaptive immunity, CLINICAL & TRANSLATIONAL IMMUNOLOGY, Vol: 9
Narean JS, Glanville N, Nunn CM, et al., 2019, Epitope mapping of antibodies induced with a conserved rhinovirus protein generating protective anti-rhinovirus immunity, Vaccine, Vol: 37, Pages: 2805-2813, ISSN: 0264-410X
Human rhinovirus (RV) infections are the principle cause of common colds and precipitate asthma and chronic obstructive pulmonary disease (COPD) exacerbations. Currently there is no vaccine for RV which is largely due to the existence of ∼160 serotypes/strains. We demonstrated previously that immunising mice with highly conserved VP4 and VP2 regions of the RV polyprotein (RV-A16 VP0) generated cross-reactive immunity to RV in vivo. The current study investigated and mapped the epitopes of RV-A16 VP0 that are targets for antibodies in serum samples from VP0 immunisation and RV challenge studies in mice. Recombinant capsid proteins, peptide pools and individual peptides spanning the immunogen sequence (RV-A16 VP0) were assessed for IgG binding sites to identify epitopes. We found that peptide pools covering the C-terminus of VP4, the N-terminus of VP2 and the neutralising NIm-II site within VP2 were bound by serum IgG from immunised mice. The NIm-II site peptide pool blocked IgG binding to the immunogen RV-A16 VP0 and individual peptides within the pool binding IgG were further mapped. Thus, we have identified immunodominant epitopes of RV vaccine candidate RV-A16 VP0, noting that strong IgG binding antibodies were observed that target a key neutralising epitope that is highly variable amongst RV serotypes.
McLean G, Girkin J, Solari R, 2019, Emerging therapeutic approaches, RHINOVIRUS INFECTIONS: RETHINKING THE IMPACT ON HUMAN HEALTH AND DISEASE, Editors: Bartlett, Wark, Knight, Publisher: ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD, Pages: 239-263, ISBN: 978-0-12-816417-4
Ho J, Siddiqui S, McIntosh M, et al., 2018, INVESTIGATION OF NOVEL MONOCLONAL ANTIBODIES DIRECTED AGAINST GLYCOPROTEIN B OF HUMAN CYTOMEGALOVIRUS FOR NEUTRALISATION IN AN IN VITRO INFECTION SYSTEM, Publisher: SPRINGER LONDON LTD, Pages: S352-S352, ISSN: 0021-1265
Baraniak I, Kropff B, McLean GR, et al., 2018, Epitope-Specific Humoral Responses to Human Cytomegalovirus Glycoprotein-B Vaccine With MF59: Anti-AD2 Levels Correlate With Protection From Viremia, JOURNAL OF INFECTIOUS DISEASES, Vol: 217, Pages: 1907-1917, ISSN: 0022-1899
Baraniak I, Kropff B, Ambrose L, et al., 2018, Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, Vol: 115, Pages: 6273-6278, ISSN: 0027-8424
Schrader JW, McLean GR, 2018, Multispecificity of a recombinant anti-ras monoclonal antibody, JOURNAL OF MOLECULAR RECOGNITION, Vol: 31, ISSN: 0952-3499
Manghera A, McLean GR, 2016, Human cytomegalovirus vaccination: progress and perspectives of recombinant gB, FUTURE VIROLOGY, Vol: 11, Pages: 439-449, ISSN: 1746-0794
Williams GR, Kubajewska I, Glanville NS, et al., 2016, The potential for a protective vaccine for rhinovirus infections., Expert Review of Vaccines, Vol: 15, Pages: 569-571, ISSN: 1744-8395
Rhinovirus (RV) infections impose a major disease burden as they cause around three out offour common colds and are responsible for the majority of acute exacerbations of chronicobstructive pulmonary disease (COPD) and asthma [1, 2]. RVs therefore are associated withan enormous economic cost in missed work or school and medical attention. Prophylacticvaccination against infection is arguably the most effective medical intervention everdeveloped, and has proven enormously effective in protecting against a large number ofdiseases. However, at the present time no effective vaccine exists for RVs. This is largelydue to the existence of 100 serotyped antigenically distinct RV strains - such variabilitymeans that a vaccine designed to elicit immune responses against a particular RV is unlikelyto be able to provide protection against the full range of virus subtypes successfully . Infact, this phenomenon was observed as early as 1965 when immunising with formalininactivated whole RV and is confirmed by the knowledge that the immunity induced followingRV infection does not significantly protect from future infection by different RV serotypes .More sophisticated attempts at immunisation with multiple inactivated RV serotypes alsofailed to induce significant cross-serotype protection . Thus, an effective cross-serotyperesponsive RV vaccine has remained elusive. The relatively recent description of a newclade of RV types (RV-C) has increased the number of identified strains/serotypes to ~160. Perhaps the quest for a RV vaccine has been dismissed as too difficult or evenimpossible, but new developments suggest that it may be feasible to generate a significantbreadth of immune protection.
McLean GR, 2014, Developing a vaccine for human rhinoviruses., Journal of Vaccines and Immunization, Vol: 2, Pages: 16-20, ISSN: 2053-1273
Rhinoviruses (RV's) are common human pathogens of the respiratory tract being the most frequent cause of mild diseases of the upper respiratory tract (common cold) but more importantly they are a major initiator of acute exacerbations of chronic airway diseases. Infections can be life threatening in the latter context however RV -induced common colds have an associated economic cost from loss of productivity due to absence from work or school. There are no appropriate antiviral therapies available and vaccine strategies have failed because of the large number of viral serotypes and the lack of cross-serotype protection generated. Here, approaches past and present for development of a vaccine to these widespread human pathogens are highlighted.
Privolizzi R, Solari R, Johnston SL, et al., 2014, The application of prophylactic antibodies for rhinovirus infections., Antivir Chem Chemother, Vol: 23, Pages: 173-177
Rhinoviruses are extremely common pathogens of the upper respiratory tract with adults experiencing on average 2-5 infections per year and children up to 12 infections. Although infections are not life threatening, except in cases of chronic lung disease where rhinoviruses are the major precipitant of acute exacerbations of disease, there is a high associated economic cost resulting from lost productivity due to absence from work or school. Treatment of infections focuses on symptom relief with anti-pyretics/analgesics as there are no antiviral therapies available and vaccine strategies face difficulties because of the large number of viral serotypes. Here, we assess the potential for prophylactic antibody intervention for these ubiquitous human pathogens.
McLean G, Glanville N, Guy B, et al., 2013, Immunization with a conserved rhinovirus capsid protein generates cross-serotype protective immune responses, Annual Congress of the British-Society-for-Immunology, Publisher: WILEY-BLACKWELL, Pages: 39-39, ISSN: 0019-2805
Mader JR, Resch ZT, McLean GR, et al., 2013, Mice deficient in PAPP-A show resistance to the development of diabetic nephropathy, JOURNAL OF ENDOCRINOLOGY, Vol: 219, Pages: 51-58, ISSN: 0022-0795
Glanville N, Mclean GR, Guy B, et al., 2013, Cross-Serotype Immunity Induced by Immunization with a Conserved Rhinovirus Capsid Protein, PLOS PATHOGENS, Vol: 9, ISSN: 1553-7374
Traub S, Nikonova A, Carruthers A, et al., 2013, An Anti-Human ICAM-1 Antibody Inhibits Rhinovirus-Induced Exacerbations of Lung Inflammation, PLOS PATHOGENS, Vol: 9, ISSN: 1553-7366
McLean GR, Walton RP, Shetty S, et al., 2013, Rhinovirus infections and immunisation induce cross-serotype reactive antibodies to VP1 (vol 95, pg 193, 2012), ANTIVIRAL RESEARCH, Vol: 97, Pages: 381-381, ISSN: 0166-3542
McLean G, Walton R, Shetty S, et al., 2012, Rhinovirus infections and immunisation induce cross-serotype reactive antibodies to VP1, European Congress of Immunology, Publisher: WILEY-BLACKWELL, Pages: 644-644, ISSN: 0019-2805
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.